Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.

Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O.

Invest New Drugs. 2020 Mar 3. doi: 10.1007/s10637-020-00915-4. [Epub ahead of print]

PMID:
32125598
2.

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.

Adnan Awad S, Kankainen M, Ojala T, Koskenvesa P, Eldfors S, Ghimire B, Kumar A, Kytölä S, Kamel MM, Heckman CA, Porkka K, Mustjoki S.

Blood Adv. 2020 Feb 11;4(3):546-559. doi: 10.1182/bloodadvances.2019000943.

3.

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.

Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, Kovanen P, Pallaud C, Ramos PM, Lähteenmäki H, Välimäki K, El Missiry M, Ribeiro A, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S.

Blood Adv. 2020 Jan 28;4(2):274-286. doi: 10.1182/bloodadvances.2019000792.

4.

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.

Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M M.D, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P.

ESMO Open. 2020 Jan;5(1). pii: e000611. doi: 10.1136/esmoopen-2019-000611.

5.

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types.

Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA.

Haematologica. 2019 Aug 22. pii: haematol.2019.217414. doi: 10.3324/haematol.2019.217414. [Epub ahead of print]

6.

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA.

Haematologica. 2020 Mar;105(3):708-720. doi: 10.3324/haematol.2018.214882. Epub 2019 Jul 11. No abstract available.

7.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Review.

PMID:
31292114
8.

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.

Karjalainen R, Liu M, Kumar A, He L, Malani D, Parsons A, Kontro M, Kallioniemi O, Porkka K, Heckman CA.

Leukemia. 2019 Oct;33(10):2548-2553. doi: 10.1038/s41375-019-0504-y. Epub 2019 Jun 7. No abstract available.

PMID:
31175323
9.

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies.

Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg KJ, Lohi O, Nykter M, Heinäniemi M.

Cancer Res. 2019 May 15;79(10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. Epub 2019 Apr 2.

10.

ERCC6L2 defines a novel entity within inherited acute myeloid leukemia.

Douglas SPM, Siipola P, Kovanen PE, Pyörälä M, Kakko S, Savolainen ER, Salmenniemi U, Orte K, Kytölä S, Pitkänen E, Porkka K, Kilpivaara O, Wartiovaara-Kautto U.

Blood. 2019 Jun 20;133(25):2724-2728. doi: 10.1182/blood-2019-01-896233. Epub 2019 Apr 1. No abstract available.

PMID:
30936069
11.

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL.

Hohtari H, Brück O, Blom S, Turkki R, Sinisalo M, Kovanen PE, Kallioniemi O, Pellinen T, Porkka K, Mustjoki S.

Leukemia. 2019 Jul;33(7):1570-1582. doi: 10.1038/s41375-018-0360-1. Epub 2019 Jan 11.

12.

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, Javarappa KK, Eldfors S, Schwaller J, Porkka K, Heckman CA.

Leukemia. 2019 Jun;33(6):1360-1372. doi: 10.1038/s41375-018-0327-2. Epub 2018 Dec 19.

PMID:
30568173
13.

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.

Poukka M, Lund-Aho T, Raittinen P, Nikkilä A, Kivinen K, Lundán T, Porkka K, Lohi O.

J Pediatr Hematol Oncol. 2019 Oct;41(7):e481-e483. doi: 10.1097/MPH.0000000000001267.

PMID:
30045148
14.

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.

Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S.

Leukemia. 2018 Jul;32(7):1643-1656. doi: 10.1038/s41375-018-0175-0. Epub 2018 Jun 20.

PMID:
29925907
15.

Germline alterations in a consecutive series of acute myeloid leukemia.

Wartiovaara-Kautto U, Hirvonen EAM, Pitkänen E, Heckman C, Saarela J, Kettunen K, Porkka K, Kilpivaara O.

Leukemia. 2018 Oct;32(10):2282-2285. doi: 10.1038/s41375-018-0049-5. Epub 2018 Apr 10. No abstract available.

PMID:
29632341
16.

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leuk Lymphoma. 2018 Dec;59(12):3002-3005. doi: 10.1080/10428194.2018.1453067. Epub 2018 Apr 4. No abstract available.

PMID:
29616861
17.

Applications of genomic medicine in the treatment of diseases.

Porkka K, Niemi M, Leppä E, Västrik I, Partanen J, Ihalainen J, Jokiranta S, Pöllänen P.

Duodecim. 2017;133(8):782-90. Review.

PMID:
29240345
18.

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.

Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA.

Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22.

19.

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

Kivioja JL, Lopez Martí JM, Kumar A, Kontro M, Edgren H, Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA.

Leuk Lymphoma. 2018 Mar;59(3):725-732. doi: 10.1080/10428194.2017.1357174. Epub 2017 Aug 4.

PMID:
28776436
20.

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.

Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen JJWM, Porkka K, Wolf D.

Leukemia. 2017 Oct;31(10):2264-2267. doi: 10.1038/leu.2017.235. Epub 2017 Jul 10. No abstract available.

PMID:
28744011

Supplemental Content

Loading ...
Support Center